---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-026872"
form_type: "8-K"
ticker: "CRBP"
cik: "0001595097"
company_name: "Corbus Pharmaceuticals Holdings, Inc."
filed_at: "2022-12-21T23:59:59+00:00"
generated_at: "2026-06-21T00:50:07.118216+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Corbus Pharma Q3 net loss $8.8M ($0.07/shr); cash $67M; CRB-601 IND on track for mid-2023

## Summary
- Net loss of $8.8M ($0.07 per share) vs $2.2M loss in Q3 2021; prior year included $12.3M tax credit.
- Operating expenses decreased to $8.2M from $14.0M, driven by lower clinical trial and manufacturing costs.
- Cash and investments $67M; amended debt agreement defers principal payments to September 2023, extending runway.
- CRB-601 pre-clinical data at SITC; IND submission on track for mid-2023.
- Actively exploring partnerships for CRB-913 (CB1 inverse agonist) for obesity.

## SEC filing metadata
- accession: 0000950170-22-026872
- form_type: 8-K
- ticker: CRBP
- cik: 0001595097
- company_name: Corbus Pharmaceuticals Holdings, Inc.
- filed_at: 2022-12-21T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1595097/000095017022026872/0000950170-22-026872-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1595097/000095017022026872/crbp-20221108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-026872
- JSON: https://secwatch.observer/filing/0000950170-22-026872.json
- Plain text: https://secwatch.observer/filing/0000950170-22-026872.txt

## Key facts
- Earnings Releases
  Corbus Pharmaceuticals Holdings, Inc. reported the three months ended September 30, 2022 results: net income net loss of approximately $8.8 million, EPS net loss per diluted share of $0.07.
  - Period: the three months ended September 30, 2022
  - Net income: net loss of approximately $8.8 million
  - EPS: net loss per diluted share of $0.07
  - Result: reported results
  source text: The Company reported a net loss of approximately $8.8 million, or a net loss per diluted share of $0.07, for the three months ended September 30, 2022
  evidence_url: https://www.sec.gov/Archives/edgar/data/1595097/000095017022026872/0000950170-22-026872-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.